SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2294Superior In-Hospital and 30-Day Outcomes with Abciximab Versus Eptifibatide: A CIcebrg-12/26/2004
2293Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-CeIcebrg-12/26/2004
2292Phase II Clinical Experience With the Novel Proteasome Inhibitor Bortezomib in PIcebrg-12/26/2004
2291[Velcade PI for Androgen-Independent Prostate Cancer] >>Urol Oncol. 2004 tuck-12/23/2004
2290[VHL expression in renal cell carcinoma sensitizes to bortezomib] >>Oncogtuck-12/21/2004
2289[Integrilin to prevent metastasis] >>Platelets and metastasis revisited: tuck-12/16/2004
2288Groundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis manny t-12/14/2004
2287ASH WEBCAST tonight at 10PM The American Society of Hematology 46th Annual MeetIan@SI-12/6/2004
2286[Bortezomib in Pediatric Patients With Refractory Solid Tumors] >> J Clintuck-12/2/2004
2285Biotechs Center Stage at ASH Confab By Adam Feuerstein Senior Writer 12/2/2004 bob zagorin-12/2/2004
2284New Data on VELCADE(R) (bortezomib) for Injection to be Presented at Upcoming Ambob zagorin-12/1/2004
2283MLNM: FDA Accepts Filing w/ Priority Review for VELCADE [delayed] Ridgeland, MS,bob zagorin-12/1/2004
2282From ASH, a free full text review of the state of the art in treating MM: ashedtuck-11/30/2004
2281GS: MLNM (IL/N): Growing pipeline with renewed focus & new technologies 52-mopgcw-11/23/2004
2280fwiw.... Street Chatter: 1. Millennium Pharmaceuticals (NASDAQ: MLNM) focuses obob zagorin-11/19/2004
2279r&d day 11/16/04 the problem with the audio in part 2 on mlnm’s site has fisoftware salesperson-11/17/2004
2278<b>G-S RESEARCH TONITE</b> At its R&D day yesterday, MLNM discuPCSS-11/16/2004
2277Very definitely on the over-promise, under-deliver list.scaram(o)uche-11/16/2004
2276I don't own it either. (eom)scaram(o)uche-11/16/2004
2275All in all, Velcade is doing (in solid tumors) much worse than I thought 12 montMiljenko Zuanic-11/16/2004
2274Figures. I recently bailed out. I should stay away from the large cap BTs (&keokalani'nui-11/16/2004
2273thanks, Ice. (eom)scaram(o)uche-11/16/2004
2272Velcade in solid tumors - part II Boronate @ Yahoo! reports from the R&D daIcebrg-11/16/2004
2271Velcade in solid tumors - part I Piper Jaffray (Thomas Wei]. MLNM :Assessing VIcebrg-11/16/2004
2270Xenova Group PLC Programme Update SLOUGH, U.K., Nov. 16, 2004 (PRIMEZONE) -- XeIcebrg-11/16/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News